Clinical and Laboratory Characteristics of Sickle Cell Anemia Patients Admitted With Fever
August 25, 2011 updated by: Dr Koren Ariel, HaEmek Medical Center, Israel
Study the Clinical and Laboratory Characteristics and the Outcome of Sickle Cell Anemia Patients Admitted to the Pediatric Ward Because of Fever as the Presenting Symptom
This study will summarized the clinical and laboratory data and the outcome of all the patients suffering from Sickle Cell Anemia (Including Sickle cell thalassemia) admitted to the pediatric ward.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The actual protocol for SCA patients admitted with fever is to obtain blood cultures and start empiric antibiotic treatment.
The study cohort included 60 SCA patients actually treated in the Pediatric Hematology Unit.
Study Type
Observational
Enrollment (Anticipated)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Afula, Israel, 18101
- Pediatric Hematology Unit - Ha'Emek Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
60 patients treated at the Pediatric Hematology Unit in the Ha'Emek Medical Center suffering from sickle cell anemia or sickle cell thalassemia admitted with fever as the presenting symptom.
Description
Inclusion Criteria: All patients admitted with fever as the only presenting symptom.
Exclusion Criteria: Patients admitted with another causes related or unrelated to sickle cell disease and have also fever.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
1
Sickle cell anemia
|
Summary of clinical and laboratory data
|
|
2
Sickle cell thalassemia
|
Summary of clinical and laboratory data
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Carina Levin, MD, Pediatric Hematology Unit - Ha'Emek Medical Center - Afula - 18101 - Israel
- Principal Investigator: Ilena Arshinov, MD, Pediatric Dpt B - Ha'Emek Medical Center - Afula - Israel
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2008
Study Completion (Actual)
November 1, 2008
Study Registration Dates
First Submitted
August 14, 2008
First Submitted That Met QC Criteria
August 14, 2008
First Posted (Estimate)
August 15, 2008
Study Record Updates
Last Update Posted (Estimate)
August 26, 2011
Last Update Submitted That Met QC Criteria
August 25, 2011
Last Verified
August 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0027-08-EMC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.